Analysts Set Tempus AI, Inc. (NASDAQ:TEM) Price Target at $56.00

Tempus AI, Inc. (NASDAQ:TEM) has been assigned an average rating of “Moderate Buy” from the twelve research firms that are covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $56.00.

Several analysts recently weighed in on TEM shares. Loop Capital lifted their price objective on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, October 15th. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and lifted their price target for the company from $45.00 to $65.00 in a report on Monday, November 11th. Bank of America increased their price objective on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Piper Sandler restated a “neutral” rating and issued a $70.00 target price (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Finally, Guggenheim assumed coverage on Tempus AI in a research report on Monday, December 9th. They set a “buy” rating and a $74.00 price target for the company.

Tempus AI Price Performance

TEM stock opened at $38.25 on Tuesday. Tempus AI has a 1 year low of $22.89 and a 1 year high of $79.49. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The stock’s fifty day moving average is $48.93 and its two-hundred day moving average is $46.74.

Insider Activity

In other news, major shareholder Bradley A. Keywell sold 395,800 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the sale, the insider now owns 16,164,449 shares in the company, valued at approximately $694,263,084.55. This represents a 2.39 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David R. Epstein sold 620 shares of Tempus AI stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total value of $25,922.20. Following the completion of the transaction, the director now owns 27,894 shares in the company, valued at $1,166,248.14. The trade was a 2.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 845,041 shares of company stock worth $35,125,473.

Institutional Trading of Tempus AI

A number of hedge funds have recently bought and sold shares of TEM. NEA Management Company LLC lifted its holdings in shares of Tempus AI by 17.8% in the third quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock valued at $304,846,000 after purchasing an additional 813,169 shares in the last quarter. Novo Holdings A S purchased a new stake in Tempus AI in the 2nd quarter worth about $142,605,000. Revolution Growth Management Company Inc. acquired a new stake in Tempus AI during the 2nd quarter worth about $128,133,000. ARK Investment Management LLC grew its stake in Tempus AI by 355.0% during the 3rd quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock valued at $134,604,000 after acquiring an additional 1,855,459 shares in the last quarter. Finally, Alphabet Inc. acquired a new position in shares of Tempus AI in the 2nd quarter valued at about $54,289,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.